|
MON2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.626032641866E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.02098362886727E-12 |
| Normal-vs-Stage2 |
1.02580000049812E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.63768998362457E-12 |
| Stage1-vs-Stage2 |
9.515600E-01 |
| Stage1-vs-Stage3 |
1.860270E-02 |
| Stage1-vs-Stage4 |
8.176100E-03 |
| Stage2-vs-Stage3 |
1.110160E-01 |
| Stage2-vs-Stage4 |
5.292300E-02 |
| Stage3-vs-Stage4 |
4.785200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.20694598549198E-14 |
| Normal-vs-AfricanAmerican |
1.95833999999673E-05 |
| Normal-vs-Asian |
1.20929999347652E-09 |
| Caucasian-vs-AfricanAmerican |
3.423400E-01 |
| Caucasian-vs-Asian |
2.688600E-01 |
| AfricanAmerican-vs-Asian |
7.169400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-16 |
| Normal-vs-Female |
1.9160228958981E-12 |
| Male-vs-Female |
5.177800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.6286971771251E-12 |
| Normal-vs-Age(41-60Yrs) |
3.87867515883045E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(81-100Yrs) |
1.185370E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.389600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.317900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.038000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.320600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.271000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.348800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.33130000357085E-08 |
| Classical-VS-Follicular |
3.288600E-01 |
| Classical-VS-Other |
8.199000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
3.91910000000495E-05 |
| Tall-VS-Other |
1.283980E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.776000E-01 |
| Follicular-VS-Normal |
4.8297000000419E-06 |
| Other-VS-Normal |
1.377940E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
2.56120014086036E-10 |
| N0-vs-N1 |
8.548200E-01 |
|
|
